AI assistant
AMGEN INC — Director's Dealing 2025
Nov 14, 2025
29819_dirs_2025-11-13_2d36b748-c1fd-4d87-892c-1cc0e91f07d7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2025-11-12
Reporting Person: Gordon Murdo (EVP, Global Commercial Ops)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-11-12 | Common Stock | S | 6879 | $336.8326 | Disposed | 41923 | Direct |
Footnotes
F1: The price reported is an average price. The prices ranged from $336.7301 to $337.0500 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.
F2: These shares include 647 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.